Teru Hideshima

USPTO Granted Patents = 14 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 32(Granted Patents)

Company Filing History:

10 out of 1,209

Dana-farber-cancer Institute Inc.

The General Hospital Corporation

patents

4. 3 out of 35

Acetylon Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12053468 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2024-08-06),

2. 11497746 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof (2022-11-15),

3. RE49240 - Inhibitors of histone deacetylase (2022-10-10),

4. 11447467 - Compounds for the degradation of STK4 and treatment of hematologic malignancies (2022-09-20),

5. 11337975 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2022-05-24),

6. 10302644 - Compositions and methods for treating multiple myeloma (2019-05-28),

7. 10172905 - Treatment of protein degradation disorders (2019-01-08),

8. 9988343 - Inhibitors of histone deacetylase (2018-06-05),

9. 9969679 - Anti-proliferative compounds and uses thereof (2018-05-15),

10. 9572854 - Treatment of protein degradation disorders (2017-02-21),

11. 9446146 - Methods and agents for improving targeting of CD138 expressing tumor cells (2016-09-20),

12. 8999289 - Treatment of protein degradation disorders (2015-04-07),

13. 8685954 - Methods and compositions for treating cancer using proteasome inhibitors (2014-04-01),

14. 8026230 - Methods and compositions for treating cancer using proteasome inhibitors (2011-09-27),

Title: Teru Hideshima: Innovator in Cancer Therapeutics

Introduction

Teru Hideshima is a prominent inventor based in Brookline, Massachusetts, known for his significant contributions to the field of pharmaceutical innovations. With an impressive portfolio of 14 patents, Hideshima has dedicated his research to developing novel therapies that aim to combat cancer.

Latest Patents

Hideshima's latest patents focus on groundbreaking pharmaceutical combinations designed to enhance cancer treatment efficacy. One notable patent outlines a combination of a histone deacetylase inhibitor and a CD38 inhibitor, detailing methods of use for the treatment or prevention of cancer. The patent emphasizes the potential of this combination in providing a therapeutically effective treatment method for patients. Another recent patent showcases a combination of a histone deacetylase 6 inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor. This invention also details its application in the treatment or prevention of cancer, marking a significant advancement in targeted cancer therapies.

Career Highlights

Throughout his career, Hideshima has been associated with prestigious institutions such as the Dana-Farber Cancer Institute and Harvard College. His research endeavors focus on the intricate mechanisms of cancer and the development of innovative therapeutic combinations, which have positioned him as a key contributor in the fight against cancer.

Collaborations

Hideshima has worked alongside notable professionals in his field, including Kenneth Carl Anderson and Ralph Mazitschek. These collaborations have enriched his research and fostered advancements in cancer therapeutics, demonstrating the importance of teamwork in driving innovation.

Conclusion

Teru Hideshima's contributions to the field of cancer treatment through his innovative patents and collaborative efforts with leading research institutions exemplify the impact of dedicated inventors in advancing medical science. His ongoing work continues to inspire future innovations that hold promise for improved cancer therapies.

This text is generated by artificial intelligence and may not be accurate.